Bli medlem
Bli medlem

Du är här


BioStock Studio: Ultimovacs reaches key milestones with UV1

Norwegian Ultimovacs has made some big announcements recently, including discussions for a fifth phase II clinical trial with universal vaccine UV1, a private placement of 270 MNOK to fund the trial and other projects, plus the FDA's decision to grant dual Fast Track designation for UV1 in advanced melanoma. To discuss this and more, Ultimovacs' CEO Carlos de Sousa linked up to the BioStock Studio remotely from Oslo for a Q&A.

Watch the interview with Carlos de Sousa at (

This is a press release from BioStock - Connecting Innovation & Capital.

Författare Cision